<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436513</url>
  </required_header>
  <id_info>
    <org_study_id>B2811002</org_study_id>
    <secondary_id>3117X3-1112</secondary_id>
    <nct_id>NCT01436513</nct_id>
  </id_info>
  <brief_title>A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.</brief_title>
  <official_title>Phase 1, Open-Label, Randomized, Single-Dose, Crossover Bioequivalence And Food Effect Study For A New Formulation Of Premarin Compared With A Reference Tablet In Japanese Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bioequivalence and food effect for a new Premarin
      formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal
      women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:Cmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:AUCall</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:Cmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:AUCall</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:Tmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:AUClast</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:AUCinf</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:MRT</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline adjusted) pharmacokinetic parameter:half-life</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:Tmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:AUClast</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:AUCinf</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:MRT</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated equilin pharmacokinetic parameter:half-life</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:half-life</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:Cmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:Tmax</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:AUClast</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:AUCall</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma unconjugated estrone (baseline unadjusted) pharmacokinetic parameter:MRT</measure>
    <time_frame>Day 1 to Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <condition>Vaginitis</condition>
  <condition>Metrorrhagia</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin reference tablet as a single oral dose under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin new tablet as a single oral dose under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin reference tablet as a single oral dose under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin new tablet as a single oral dose under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin reference tablet (fasted)</intervention_name>
    <description>Premarin reference tablet, single dose, fasted conditions</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin new tablet (fasted)</intervention_name>
    <description>Premarin new tablet, single dose, fasted conditions</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin reference tablet (fed)</intervention_name>
    <description>Premarin reference tablet, single dose, fed conditions</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin new tablet (fed)</intervention_name>
    <description>Premarin new tablet, single dose, fed conditions</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese healthy postmenopausal women

        Exclusion Criteria:

          -  History or current evidence of thrombophlebitis, thromboembolic disorders, or any
             coagulopathies.

          -  History or presence of malignancy or estrogen-dependent neoplasia. Subjects with a
             documented history of any malignancy, except for basal or squamous cell carcinoma of
             skin, which has been treated and fully resolved for a minimal 5 years.

          -  History or presence of benign or malignant liver tumor that developed during the use
             of oral contraceptives or other estrogen-containing products.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2811002&amp;StudyName=A%20Study%20To%20Compare%20The%20Amount%20Of%20Premarin%20Components%20That%20Is%20Absorbed%20Into%20The%20Blood%20Of%20Japanese%20Healthy%20Postmenopausal%20Women%20Followin</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bioequivalence</keyword>
  <keyword>menometrorrhagia</keyword>
  <keyword>climacteric disturbance</keyword>
  <keyword>Estrogen Replacement Therapy</keyword>
  <keyword>Estrogens Conjugated</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

